Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | BTK | Q06187 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 9/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26644930 | 1.00 | JAK3 (0.40) | JAK3ROCK2CYP3A4BTKEGFR | |
| SCHEMBL30622881 | 0.89 | CCNT1 (0.42) | JAK3ROCK2CYP3A4BTKGSK3A | |
| SCHEMBL26645323 | 0.89 | CCNT1 (0.42) | JAK3ROCK2CYP3A4BTKGSK3A | |
| SCHEMBL30622314 | 0.87 | JAK3 (0.41) | JAK3ROCK2BTK | |
| SCHEMBL26644884 | 0.87 | JAK3 (0.41) | JAK3ROCK2BTK | |
| SCHEMBL26644864 | 0.84 | JAK3 (0.42) | JAK3BTKEGFR | |
| SCHEMBL30622304 | 0.84 | JAK3 (0.42) | JAK3BTKEGFR | |
| SCHEMBL30622362 | 0.83 | JAK3 (0.43) | JAK3BTKEGFR | |
| SCHEMBL26644962 | 0.83 | JAK3 (0.43) | JAK3BTKEGFR | |
| SCHEMBL30622390 | 0.82 | CSNK1E (0.41) | BTKEGFRGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | claimed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | claimed |
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | disclosed |